APMD vs WVE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
APMD · Apnimed$15.10 ▲ 6.64%
WVE · Wave Life Sciences$3.37 ▲ 4.50%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- APMD -39.6%
- WVE -38.8%
Head to head
| Metric | APMD | WVE |
|---|---|---|
| Price | $15.10 | $3.37 |
| Change today | ▲ 6.64% | ▲ 4.50% |
| Market cap | $628.62M | $663.68M |
| Return, 3 months | -46.0% | -44.6% |
| Return, year to date | – | -80.2% |
| Return, 1 year | – | -57.2% |
| P/E (TTM) | 3.9 | – |
| P/B | -3.6 | 1.7 |
| P/E percentile vs own 5y | 25th | 64th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -29.4% | +72.9% |
| Net profit growth (YoY) | +281.3% | -15.0% |
| Gross margin | 93.9% | – |
| Operating margin | 30.9% | -320.9% |
| Net margin | 252.6% | -296.9% |
| Return on equity | – | -80.0% |
| Analyst target vs. price | +233.3% | +410.3% |
| Analyst buy share | 100% | 94% |
| RSI (14) | 35 | 44 |
| 30-day volatility | 91.5% | 64.8% |
| Max drawdown, 1 year | -56.5% | -85.5% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- WVE is the largest of the group by market value.
- WVE is growing revenue fastest.
- APMD keeps the most profit per dollar of sales.
- WVE has been the calmest stock over the last 30 days.